#Fulvestrant

[phonemantra-blog]

 Faslodex in Cancer Treatment Faslodex, also known by its generic name fulvestrant, is a crucial medication in the fight against certain types of breast cancer. It belongs to a class of drugs called estrogen receptor antagonists. This means it works by blocking the effects of estrogen in the body, which is a hormone that can promote the growth of breast cancer cells. What is Faslodex? faslodex Faslodex functions by binding to the estrogen receptors in cancer cells, effectively neutralizing their ability to receive signals from estrogen. This action inhibits the growth of estrogen-dependent cancer cells, an essential factor in treating hormone receptor-positive breast cancer. Conditions Treated with Faslodex Faslodex is primarily used in the treatment of hormone receptor-positive breast cancer, specifically in postmenopausal women. It is typically recommended when other hormone therapies have proven ineffective. Benefits and Efficacy The efficacy of Faslodex in treating hormone receptor-positive breast cancer is well-documented. Here are some key benefits: Tumor Suppression: Faslodex effectively suppresses the growth of estrogen-dependent cancer cells, slowing down or halting the progression of the disease. Improved Survival Rates: Studies have shown that Faslodex can lead to increased survival rates in individuals with advanced breast cancer, offering hope and extended quality of life. Lower Recurrence Risk: When used as an adjuvant therapy, Faslodex reduces the risk of cancer recurrence, providing long-term protection. Manageable Side Effects: While side effects are possible, Faslodex is generally well-tolerated, and its benefits often outweigh any adverse effects. Administration and Dosage Faslodex is typically administered via intramuscular injection, most commonly into the buttocks. The frequency of injections may vary, but it is often administered once a month, under the supervision of a healthcare provider. Side Effects and Safety While Faslodex is generally well-tolerated, like any medication, it may come with potential side effects. Common side effects include: Injection site pain or discomfort Nausea Headache Hot flashes Weakness Joint pain Alternative Treatments While Faslodex is a vital component of breast cancer treatment, it's essential to be aware of complementary therapies and alternative treatments that may enhance overall well-being. These may include: Hormone Therapies: Other hormone therapies such as aromatase inhibitors or targeted therapies like CDK4/6 inhibitors may be considered in combination with Faslodex. Chemotherapy: In certain cases, chemotherapy may be recommended alongside Faslodex. Lifestyle Changes: A healthy lifestyle, including regular exercise and a balanced diet, can complement medical treatment and improve overall health. Supportive Therapies: Counseling, support groups, and integrative therapies like acupuncture or yoga can provide emotional and physical support during treatment. Future Developments Cancer research is a dynamic field, and ongoing studies aim to enhance the efficacy and accessibility of Faslodex and similar treatments. Stay informed about the latest developments in breast cancer research, including: Clinical Trials: Learn about ongoing clinical trials exploring new treatments and combinations involving Faslodex. Emerging Therapies: Discover potential breakthroughs in breast cancer therapies and how they may impact treatment strategies. Patient Advocacy: Explore opportunities to engage in patient advocacy and contribute to advancing breast cancer care. FAQs on the topic of "Faslodex": FAQ 1: What is Faslodex used for in cancer treatment? Answer: Faslodex is primarily used to treat hormone receptor-positive breast cancer, particularly in postmenopausal women. FAQ 2: How does Faslodex work in the body? Answer: Faslodex functions by binding to estrogen receptors in cancer cells, blocking their response to estrogen and inhibiting cell growth. FAQ 3: What are the benefits of Faslodex treatment? Answer: Faslodex offers benefits such as tumor suppression, increased survival rates, reduced recurrence risk, and manageable side effects in breast cancer care. FAQ 4: Are there any side effects associated with Faslodex? Answer: Common side effects of Faslodex may include injection site discomfort, nausea, headache, hot flashes, weakness, and joint pain. Severe side effects are rare but possible. FAQ 5: How is Faslodex administered to patients? Answer: Faslodex is typically administered via intramuscular injection, often once a month, under the supervision of a healthcare provider. FAQ 6: Are there alternative treatments to Faslodex for breast cancer? Answer: Yes, alternative treatments may include other hormone therapies, chemotherapy, lifestyle changes, and supportive therapies, depending on individual circumstances. FAQ 7: Can Faslodex be used in combination with other cancer treatments? Answer: In some cases, Faslodex may be used in combination with other therapies, such as aromatase inhibitors or targeted therapies, to enhance treatment outcomes. FAQ 8: What should patients expect during Faslodex treatment? Answer: Patients can expect ongoing monitoring, potential side effects, and regular discussions with their healthcare provider to assess treatment effectiveness. FAQ 9: Are there ongoing clinical trials involving Faslodex? Answer: Yes, there are clinical trials exploring new uses and combinations of Faslodex, offering opportunities for patients to participate in cutting-edge research. FAQ 10: How can patients stay informed about the latest developments in breast cancer care, including Faslodex? Answer: Patients can stay informed by following reputable cancer support organizations, clinical trials information, and educational breast cancer resources for updates and advocacy opportunities. Conclusion In this comprehensive guide, we've explored the critical role of Faslodex in the treatment of hormone receptor-positive breast cancer. From its mechanism of action to its benefits, dosage guidelines, and patient experiences, you now have a thorough understanding of this medication.

[medicomunicare]

Clinical trials for hormone-positive resistant breast cancer: exploring kinase inhibitors and ER-modulators

Clinical trials for hormone-positive resistant breast cancer: exploring kinase inhibitors and ER-modulators

Patients with hormone receptor (ER)-positive, growth factor receptor (Her2)-negative breast cancer are commonly treated in the first line with an endocrine therapy (such as an aromatase inhibitor like anastrozole, which blocks the production of estrogens) alongside a CDK4/6 inhibitor, which stalls the cell cycle. Eventually, however, most tumors develop resistance to these therapies, and options…

[allaboutpharma]

This page contains information about Fulvestrant-D5. Buy high quality Fulvestrant-D5 from SimSon Pharma Limited

[indianph]

Palbociclib can interact with other medications, potentially affecting its efficacy or safety. For instance, strong CYP3A inhibitors and inducers can alter palbociclib 125 mg price and drug levels in the body and should be used cautiously. Additionally, medications that elevate gastric pH may reduce Palbociclib’s effectiveness. However, no significant interactions have been observed with drugs like letrozole, fulvestrant, or goserelin. Proper understanding of these interactions is vital for safe treatment. For detailed information on drug interactions and pricing, feel free to contact us via Call/WhatsApp: +91 8130290915.

[global-online-pharmacy]

Ribociclib Kisqali Medication uses, side effects & Lowest cost

Ribociclib is used in combination with another medication to treat a certain type of hormone receptor– positive (depends on hormones such as estrogen to grow) advanced breast cancer or that has spread to other parts of the body in women who have not experienced menopause (change of life; end of monthly menstrual periods) and in those who are close to or who have already experienced menopause. Ribociclib is also used in combination with fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive advanced breast cancer or that has spread to other parts of the body as an initial treatment or in people who have not been treated successfully with other treatments in women who have already experienced menopause.

How should this medicine be used?

Ribociclib comes as a tablet to take by mouth. It is usually taken with or without food once daily in the morning for the first 21 days of a 28-day cycle. Take ribociclib at around the same time every day.

What side effects can this medication cause?

Ribociclib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: diarrhea constipation, stomach pain, headache, hair loss, back pain itching, mouth sores, swelling of the hands, feet, ankles, or lower legs difficulty falling asleep or staying asleep

Above content source:  https://www.911globalmeds.com/info/213-1-Ribociclib-Kisqali-Kryxana-Medication-Patient-Information-In-English.pdf

The guaranteed Lowest Cost of Ribociclib / Kisqali 200 mg @ $34.05 and $6.50 per Tablet Online.

Above Price source:

[bidhuan]

FDA Memberikan Peninjauan Prioritas untuk Inavolisib dalam Pengobatan Kanker Payudara dengan Mutasi PIK3CA

Majalah Farmasetika – Peninjauan prioritas inavolisib adalah untuk pengobatan pasien dengan kanker payudara lanjut yang reseptor hormonnya positif, HER2-negatif dengan mutasi PIK3CA. FDA telah memberikan peninjauan prioritas untuk inavolisib (GDC-0077; Roche) dalam kombinasi dengan palbociclib (Ibrance; Pfizer) dan fulvestrant (Faslodex; AstraZeneca), mempercepat aksesibilitas bagi pasien yang…

[arrangoiz]

Monaleesa-3 Trial in Metastatic Breast Cancer

The CDK 4/6 inhibitors are a class of oral drugs that have been approved for HR+, HER2-negative metastatic breast cancer in the first-line setting or after progression on prior aromatase inhibitor In the MONALEESA-3 trial: Ribociclib in combination with fulvestrant: Showed progression-free survival (20.5 months vs. 12.8 months) and overall survival benefit over fulvestrant alone in HR+,…

[novaglobalhealthcare]

FDA approves capivasertib with fulvestrant for breast cancer

On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

FDA also approved the FoundationOne®CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with capivasertib with fulvestrant.

The full prescribing information for Truqap will be posted here.

Efficacy was evaluated in CAPItello-291 (NCT04305496), a randomized, double-blind, placebo-controlled, multicenter trial in 708 patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer, of which 289 patients had tumors with PIK3CA/AKT1/PTEN-alterations. All patients were required to have progression on aromatase inhibitor-based treatment. Patients could have received up to two prior lines of endocrine therapy and up to 1 line of chemotherapy for locally advanced or metastatic disease.

Patients were randomized (1:1) to either capivasertib 400 mg or placebo administered orally twice daily for 4 days, followed by 3 days off treatment each week over a 28-day treatment cycle. Both investigational and control arm patients received Fulvestrant 500 mg intramuscularly on cycle 1 days 1 and 15, and then every 28 days thereafter. Patients received therapy until disease progression or unacceptable toxicity.

The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) in the overall population and in the population of patients whose tumors had PIK3CA/AKT1/PTEN-alterations evaluated according to RECIST, version 1.1. A statistically significant difference in PFS was observed in the overall population and in the population of patients whose tumors have PIK3CA/AKT1/PTEN-alteration(s).

In the 289 patients with PIK3CA/AKT1/PTEN-altered tumors, the median PFS was 7.3 months (95% CI: 5.5, 9.0) in the capivasertib-fulvestrant group and 3.1 months (95% CI: 2.0, 3.7) in the placebo-fulvestrant group (Hazard Ratio [HR] 0.50 [95% CI: 0.38, 0.65] p-value< 0.0001).

An exploratory analysis of PFS in the 313 (44%) patients whose tumors did not have a PIK3CA/AKT1/PTEN-alteration showed a HR of 0.79 (95% CI: 0.61, 1.02), indicating that the difference in the overall population was primarily attributed to the results seen in the population of patients whose tumors have PIK3CA/AKT1/PTEN-alteration.

The most common adverse reactions (reported in ≥20% of patients), including laboratory abnormities were diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting and stomatitis.

The recommended capivasertib dose is 400 mg orally twice daily (approximately 12 hours apart), with or without food, for 4 days followed by 3 off days until disease progression or unacceptable toxicity.

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, Israel’s Ministry of Health (IMoH), Singapore’s Health Sciences Authority (HSA), Switzerland's Swissmedic, and United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). The application reviews are ongoing at the other regulatory agencies.

[smiithwalkerr]

Abemaciclib in combination with fulvestrant for advanced or metastatic breast cancer after prior endocrine therapy

Breast cancer, a cancer that develops from the tissues of the breast, is the most common cancer in the UK. There are many types of breast cancer and they are often grouped based on the presence or absence of some specific types of proteins (‘receptors’) in the cells of the patient. The most common type of breast cancer are those that are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). The advanced form of the HR+ and HER2- breast cancer occurs when the cancer has spread to other parts of the body such as the bones, brain and liver.

Abemaciclib is a new drug that is being developed for patients with the HR+/HER2- type of advanced breast cancer. The drug is being developed to be given in combination with fulvestrant, a drug that is already in use for the treatment of advanced breast cancer. Abemaciclib works differently from other drugs by targeting a very specific type of enzyme produced by cancer cells in patients with HR+/HER2- breast cancer. Abemaciclib is taken orally while fulvestrant is given by injection. If approved, the combination of both drugs will offer additional treatment options for patients with advanced HR+/HER2- breast cancer that have not responded well to other drugs.

[larvolclinic9]

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving sorafenib together with fulvestrant may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving sorafenib together with fulvestrant works in treating patients with locally advanced or metastatic breast cancer that did not respond to aromatase inhibitor therapy.Condition or disease Intervention/treatment Phase Breast CancerDrug: fulvestrantDrug: sorafenib tosylatePhase 2

Detailed Description:

OBJECTIVES:

Primary

To investigate the clinical activity of sorafenib tosylate and fulvestrant, as determined by a 4-month progression-free survival rate, in patients with hormone receptor-positive locally advanced or metastatic breast cancer that progressed after prior treatment with an aromatase inhibitor.

Secondary

To determine the objective response rate in patients treated with this regimen.

To determine the median time to progression in patients treated with this regimen.

To determine the progression-free survival of patients treated with this regimen.

To determine the overall survival of patients treated with this regimen.

To establish the safety and tolerability profile of this regimen in these patients.

OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-28. Patients also receive fulvestrant intramuscularly on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 28-56 days.

Study Design

MedlinePlus Genetics related topics: Breast cancer

MedlinePlus related topics: Breast Cancer

Drug Information available for: Fulvestrant Sorafenib

Genetic and Rare Diseases Information Center resources: Breast Cancer, Male

U.S. FDA Resources

[edenmartinez]

Breast cancer receptor status should by Gissel Rendom

desesprinde ⚫part of the diagnostic work of Cancer, including diagnosed or recurrent for patient with psycho Here state by no histochemistry with or within Fluorescence in situ hybridization if needed cand HR Status including ER and PR 13 several gene expression assays are avalaible That can help predict risk of recurrence and response to systemic therapy ! More Ready has been germine mutation testing especored ento mannegements of" Looking for BREA mutation

 To guide agovant Therapy Select on For patient with Herz 2 negative breast cancer. "Lasly measurement of the Ki-67 antigen can be helpful when Considering specific Targeted Therapies such as abemaciclib at the beginning of breast tumor. Among why Like driver patient with metastasis, her 2 positive! Breast cancer approximately 80% will develop in the brain. The early breast cancer based on disease characteristic and risk Sequencing papilla therapies  with He g2 

Question: ASK CDK4 inhibitor to ANZ KI 67N when the byopsi is clear

Byopsi with ultrasound

Treatment medical

Table of medicaments

Ribociclib 600 mg (there 200mg tablets) once daily for 3 weeks, once dayly for 3 weeks followed by week without taking kisqali

Letrozole or anastrozole 

Follow your doctors  recommended dosing Schedule.

Fulvestrant when taken with kisqali

500 mg doce on days 1,15 and 29 during the first month of treatment, and 500 mg doce once monthly thereafter.

Take the recommended dose of KISQALI® (ribociclib) once each day at about the same time, preferably in the morning

You can take KISQALI either with or without food

Swallow KISQALI tablets whole with a glass of water. Do not chew, crush, or split the tablets

Do not take any KISQALI tablets that are broken, cracked, or that look damaged

Avoid grapefruit and grapefruit juice while taking KISQALI

If you miss a dose of KISQALI or vomit after taking a dose of KISQALI, do not take another dose on that day. Take your next dose at your regular time

If you take too much KISQALI, call your doctor right away or go to the nearest hospital emergency room

Diagnosis may help patients and caregivers: oitential to reduce stigma, alleviate feelings of gult or blame for individuals and caregivers, initiation of multidisciplinared care, preventio of future unnecesary testing

ormone receptor-positive, HER2-negative early stage breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could represent an alternative to multiagent chemotherapy. We aimed to evaluate the biological and clinical activity of neoadjuvant ribociclib plus letrozole in the luminal B subtype of early stage breast cancer.

Methods

CORALLEEN is a parallel-arm, multicentre, randomised, open-label, phase 2 trial completed across 21 hospitals in Spain. We recruited postmenopausal women (≥18 years) with stage I–IIIA hormone receptor-positive, Eastern Cooperative Oncology Group Performance Status 0–1, HER2-negative breast cancer and luminal B by PAM50 with histologically confirmed, operable primary tumour size of at least 2 cm in diameter as measured by MRI. Patients were randomly assigned (1:1) using a web-based system and permuted blocks of 25 to receive either six 28-days cycles of ribociclib (oral

Type of genetic obesity

Syndromic

Prader willi

Pharamecutical molécula

Oxytocin

Mode of administration

Intranasal 

N= 24 result pws 19-69 years Double- blindrc,  one simple doce (oxytocin vs placebo)

Number of cases

5 on going Trials Phase(II and III)

Result

Significan Increase in trust in other and decrease in sadnes tendencias (P=0,02) with les disruptive behavior

(P=0,03) in the day 2 days Following administration tan parts with placebo

Mechanism in Endocrinology update on treatment for patient with genetic obesity

The idstinntion between syndromic does non syndromic monogenic obesity his its limitation as clinical y certain forms of obesity can be accompanied by neuro developmental and/or psychiatric disorder In addition, There is a overlap in their photo-physiology, as mostreate forms of obesity involve central anormalityes. Common forms migh also benefic from the development in the future

Pathology of breast cancer in pregnancy

Aminoglycosides )otototrial amphotericin B)nefrotoricies Chloramphenicol. Nitrofurantorna, endefficient hemolysis of glucose 6-p (sulfonamide dehydrogenated as nitrofurenntoine, kerniterus, tetracycline, teething disorders)  

Grupo A:

 Amikacina, ampicilina, carbonicilina, clindamicinina, Cloranfenicol, Eritomicina, Gentamicinia, niacida, kanamicina, meticilina.

Sulfamidas: Cotrimoñole, Tetraciclina, Tobramicina.

Sangre __ Antimicrobials in breast milk

Grupo B: 

Concentration plasmatic easily absorbable in bresast mkilk but with risk for the breastfed.

Grupo C: Concentatrion   almost in breast milk for the breastfed

Nitrofuratoina

Acido Nalidixi

Metronidazol

600 mg once daily for 3 weeks on, 1 week off) plus daily letrozole (oral 2·5 mg/day) or four cycles of doxorubicin (intravenous 60 mg/m2) and cyclophosphamide (intravenous 600 mg/m2) every 21 days followed by weekly paclitaxel (intravenous 80 mg/m2) for 12 weeks. The total duration of the neoadjuvant therapy was 24 weeks. Randomisation was stratified by tumour size and nodal involvement. Samples were prospectively collected at baseline (day 0), day 15, and surgery. The primary endpoint was to evaluate the proportion of patients with PAM50 low-risk-of-relapse (ROR) disease at surgery in the modified intention-to-treat population including all randomly assigned patients who received study drug and had a baseline and at least one post-baseline measurement of ROR score. The PAM50 ROR risk class integrated gene expression data, tumour size, and nodal status to define prognosis. This trial was registered at ClinicalTrials.gov, NCT03248427.

Findings